These developments unfolded during a period marked by broader medtech slowdowns — from regulatory backlogs to lingering effects of the fall government shutdown — as well as a fundraising environment that can be challenging for early-stage medtech companies.
—
Malana VanTyler,
USA Today,
17 Jan. 2026
Without subscriber data, investors cannot see growth slowdowns early, raising the risk of sharp stock declines when results disappoint.
Examples are automatically compiled from online sources to
show current usage.Read More
Opinions expressed in the examples do not represent those of Merriam-Webster or its editors.
Send us feedback.